Committee Vote: 8 YES and 2 NO
Great job by all the Mesoblast team members today. Very professional presentations. Honorable mention to Dr. Kurtzberg who helped carry the day on the issue of approving based on a single arm study. It's hard to argue against a front-line clinician of her stature who has treated over 30 children with remestemcel-L. She did an excellent job in subdued but effective tones describing the suffering these children go through and the "dramatic" results remestemcel-L affords them. I lost sound at the end when each committee member discussed reasoning behind his or her vote. The two no votes were from an adult oncologist at the NIH who is a hardliner about doing blinded controlled 2-arm trials. The other NO vote came from the patient representative, ie a lay person there to represent patients. I don't know what that is all about, would have liked to have heard her explanation. In any event it's a relief to have this behind us. FDA usually follows committee recommendations. Mesoblast planning to do an adult double-blinded trial in adults I think should provide further sway for the FDA to approve this in suffering children. Looking forward to the first interim read out now on C-19 ARDS. We're in for some exciting times. Many thanks and glta. HODL !!
- Forums
- ASX - By Stock
- MSB
- Ryoncil: ODAC/FDA Meeting Discussion
Ryoncil: ODAC/FDA Meeting Discussion, page-1734
-
-
- There are more pages in this discussion • 313 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $5.496M | 4.674M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
56 | 76791 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 52932 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
56 | 85944 | 1.160 |
31 | 79092 | 1.155 |
14 | 207571 | 1.150 |
12 | 196738 | 1.145 |
7 | 194400 | 1.140 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 96663 | 17 |
1.175 | 99352 | 12 |
1.180 | 78334 | 11 |
1.185 | 39803 | 4 |
1.190 | 62000 | 4 |
Last trade - 15.44pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online